Dutch company Gist-Brocades says that it is likely it will increase its 20% minority interest in Bio-Intermediair International Holdings, the Groningen, Netherlands-based biopharmaceutical company.
However, it says that no further details on this will be given at this stage. Bio-Intermediair is an independent provider of manufacturing services, specializing in pilot to large-scale cell cultures and production of biopharmaceuticals for therapeutic applications. Gist-Brocades, with 1995 turnover of 1.84 billion guilders ($1.11 billion), is a leading producer of baker's yeast, penicillin and enzymes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze